股票行情快报：新华医疗（600587）2月5日主力资金净买入56.31万元

Core Viewpoint - Xinhua Medical (600587) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [1] Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [1] - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year [1] - The non-recurring net profit was 370 million yuan, reflecting a decline of 38.98% year-on-year [1] - In Q3 2025, the company recorded a single-quarter main revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year [1] - The single-quarter net profit attributable to shareholders was 48.59 million yuan, down 63.39% year-on-year [1] - The single-quarter non-recurring net profit was 37.66 million yuan, a decline of 71.77% year-on-year [1] - The company's debt ratio stands at 45.85%, with investment income of 48.28 million yuan and financial expenses of 21.30 million yuan [1] - The gross profit margin is reported at 25.11% [1] Market Activity - As of February 5, 2026, Xinhua Medical's stock closed at 15.45 yuan, down 0.58% with a turnover rate of 0.96% [1] - The trading volume was 57,800 hands, with a total transaction amount of 89.46 million yuan [1] - On February 5, the net inflow of main funds was 563,100 yuan, accounting for 0.63% of the total transaction amount [1] - The net inflow of speculative funds was 2.8369 million yuan, representing 3.17% of the total transaction amount [1] - Retail investors experienced a net outflow of 3.4001 million yuan, which is 3.8% of the total transaction amount [1] Analyst Ratings - In the last 90 days, two institutions have given ratings for Xinhua Medical, both recommending an increase in holdings [2] - The average target price set by institutions in the past 90 days is 20.0 yuan [2]